Evidence map›Paper›PMID 39222676›Full record

ArticleCancer letters2024

Hepatocyte growth factor promotes melanoma metastasis through ubiquitin-specific peptidase 22-mediated integrins upregulation.

Qiong Gao, Na Li, Yujie Pan, Peng Chu, Yuanzhang Zhou, Huijun Jia, Yang Cheng, Guoqing Xue, Jiankun Song, Yue Zhang and 5 more

Abstract read
In one paragraph

Article in Cancer letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qiong GaoDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Na LiDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Yujie PanDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Peng ChuDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Yuanzhang ZhouDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Huijun JiaDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Yang ChengDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Guoqing XueDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Jiankun SongDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Yue ZhangDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Houyu ZhuDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Jia SunDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Bin ZhangDepartment of Medicine, Hematology/Oncology Division, Robert H. Lurie Comprehensive Cancer Center, USA.
Zhaolin SunDepartment of Biochemistry and Molecular Biology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China. Electronic address: zlsun56@yeah.net.
Deyu FangDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Department of Medicine, Hematology/Oncology Division, Robert H. Lurie Comprehensive Cancer Center, USA. Electronic address: fangd@northwestern.edu.

Funding

Novel Role of Hepatic SEL1L-HRD1 ERAD in FGF21 Gene TranscriptionR01DK120330 · NIDDK · UNIVERSITY OF VIRGINIA · PI Deyu Fang, Ling Qi · 2018 to 2026
$4.9M
Clinical analysis and therapeutic development of exosomal ACE2R01AI167272 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Deyu Fang, Huiping Liu · 2022 to 2026
$3.6M
VPS72 controls Treg cell stability and adaptation to tumor microenvironmentR01CA284740 · NCI · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · PI FANG, DEYU, MI, QING-SHENG · 2023 to 2025
$3.1M
A deubiquitination module controls Treg adaptation to tumor microenvironmentR01CA257520 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU, ZHANG, BIN · 2021 to 2025
$2.8M
Regulation of Rhythmic m6A RNA Modification by ER‐associated DegradationR01DK126908 · NIDDK · WAYNE STATE UNIVERSITY · PI FANG, DEYU, ZHANG, KEZHONG · 2021 to 2024
$2.2M
Targeting a Treg deubiquitinase in antitumor immune therapyR01CA232347 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU · 2018 to 2022
$1.7M
Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus TherapyR01AR066634 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU, ZHANG, KEZHONG · 2014 to 2018
$1.7M
The roles of Synoviolin in immune tolerance and autoimmunityR01AI108634 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU · 2014 to 2017
$1.5M
Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat the triple negative breast cancerR01CA288387 · NCI · NORTHWESTERN UNIVERSITY · PI Deyu Fang, Huiping Liu · 2025 to 2026
$1.3M
NCI NIH HHS R01 CA232347NCI NIH HHS R01 CA257520NCI NIH HHS R01 CA284740NCI NIH HHS R01 CA288387NIAID NIH HHS R01 AI108634NIAID NIH HHS R01 AI167272NIAMS NIH HHS R01 AR066634NIDDK NIH HHS R01 DK120330NIDDK NIH HHS R01 DK126908
6 · The paper itself

Abstract

Hepatocyte growth factor (HGF) plays a critical role in promoting tumor migration, invasion, and metastasis, partly by upregulating integrins. The molecular mechanisms behind how HGF facilitates integrin-mediated tumorigenesis are not fully understood. In this study, we demonstrate that the ubiquitin-specific peptidase 22 (USP22) is essential for HGF-induced melanoma metastasis. HGF treatment dramatically increased the expression of both USP22 and multiple integrin family members in particular ITGAV, ITGB3, and ITGA1. An unbiased analysis of the TCGA database reveals integrins as common downstream targets of both USP22 and HGF across multiple human cancer types. Notably, CRISPR-mediated deletion of USP22 completely eliminates HGF-induced integrin expression in melanoma cells. At the molecular level, USP22 acts as a bona fide deubiquitinase for Sp1, a transcription factor for the ITGAV, ITGB3, and ITGA1 genes. USP22 interacts with and inhibits Sp1 ubiquitination, protecting against Sp1 proteasomal degradation. Supporting this, immunohistology analysis detects a positive correlation among USP22, Sp1, and integrin αv in human melanoma tissues. This study identifies the death from the signature gene USP22 as a critical positive regulator for HGF-induced integrin expression by deubiquitinating the Sp1 transcription factor during melanoma metastasis.

Indexed as

Gene Expression Regulation, NeoplasticHepatocyte Growth FactorMelanomaSp1 Transcription FactorUbiquitin ThiolesteraseUp-RegulationAnimalsCell Line, TumorCell MovementHumansIntegrinsMiceNeoplasm MetastasisSkin NeoplasmsUbiquitinationHepatocyte Growth FactorHGF protein, humanIntegrinsSP1 protein, humanSp1 Transcription FactorUbiquitin ThiolesteraseUsp22 protein, human

Identifiers

PMID39222676
PMCPMC11542356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.